SoniVie receives IDE approval from FDA for its Pilot study to treat Hypertension with its Renal Artery Denervation TIVUS™ technology

TEL AVIV, Israel, June 20, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted…

New app from Health in Transportation & NuraLogix allows drivers to perform CDL health checks that target hypertension and type-2 diabetes.

DETROIT, June 8, 2022 /PRNewswire/ — Professional drivers, working both in mass transit and in trucking, are now able to access a 30-second CDL health check that focuses on the dangers of hypertension and type-2 diabetes by utilizing a new…

Merck Foundation Marks World Hypertension Day 2022 in Partnership With African First Ladies by Building Cardiovascular, Diabetes, and Endocrinology Care Capacity in Africa

Business Wire India Merck Foundation, the philanthropic arm of Merck KGaA Germany marks World Hypertension Day 2022 in partnership with African First Ladies, Ministries of Health, Medical Societies and Academia, through their long-term commitment toward building Cardiovascular, Diabetes, and Endocrinology…

Merck Foundation and African First Ladies mark World Hypertension Day 2021 by Building Cardiovascular, Diabetes, and Endocrinology Care Capacity in Africa, Asia and Latin America

Business Wire India Merck Foundation in partnership with African First Ladies and Ministries of Health continues to provide their scholarship of one-year Post-Graduate Diploma and two-year Master degree in both Preventive Cardiovascular Medicine, Endocrinology and Diabetes for 628 doctors from…

Merck Foundation marks Merck Foundation and African First Ladies Mark World Hypertension Day 2021 by Building Cardiovascular, Diabetes, and Endocrinology Care Capacity in Africa, Asia and Latin America

Business Wire India Merck Foundation in partnership with African First Ladies and Ministries of Health continues to provide their scholarship of one-year Post-Graduate Diploma and two-year Master degree in both Preventive Cardiovascular Medicine, Endocrinology and Diabetes for 628 doctors from…

ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypertension

PALO ALTO, Calif., May 16, 2021 /PRNewswire/ — ReCor Medical, Inc. (“ReCor”), a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., today presented the primary endpoint data from the randomized sham-controlled RADIANCE-HTN TRIO (“TRIO”) study.  In subjects with resistant hypertension, those treated…

Merck Foundation crusades against hypertension

Merck Foundation marks World Hypertension Day 2019 Merck Foundation, the philanthropic arm of Merck KGaA Germany marked ‘World Hypertension Day 2019’ by building hypertension care capacity in Africa and Asia through their nationwide programs. “Merck Foundation launched ‘Merck Hypertension Award’…

Nicox Extraordinary General Meeting of July 11, 2022

Nicox Extraordinary General Meeting of July 11, 2022 Sophia Antipolis, June 22, 2022 Dear valued Shareholder, This letter is sent to ask for your continued valuable support for Nicox by voting in the Company’s upcoming Extraordinary General Meeting convened on…

BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director

June 20, 2022News release BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director COPENHAGEN, DENMARK and BOSTON, MA, USA, June 20, 2022, (GLOBE…

Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO

Preliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genentech and conducted at Memorial Sloan Kettering Cancer Center, New York, United States Autogene Cevumeran, a fully individualized mRNA cancer immunotherapy (iNeST) demonstrated that…